| Recruiting | Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROM NCT06948786 | University of Washington | Phase 2 |
| Withdrawn | A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Foll NCT06068881 | Epizyme, Inc. | Phase 2 |
| Recruiting | Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810 | Mayo Clinic | Phase 1 |
| Terminated | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19 NCT06343376 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cycloph NCT06191887 | Mayo Clinic | Phase 1 |
| Recruiting | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy NCT05848765 | University of Birmingham | Phase 2 |
| Recruiting | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies NCT05453396 | University of Washington | Phase 2 |
| Active Not Recruiting | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies NCT05828589 | BeOne Medicines | Phase 1 |
| Withdrawn | Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicula NCT05152459 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have R NCT05627245 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Zandelisib + Tazemetostat in R/R Follicular Lymphoma NCT05604417 | Jacob Soumerai, MD | Phase 1 / Phase 2 |
| Withdrawn | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym NCT04635683 | Yazeed Sawalha | Phase 1 |
| Withdrawn | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma NCT04836832 | Narendranath Epperla | Phase 1 |
| Terminated | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Rel NCT04699461 | ADC Therapeutics S.A. | Phase 2 |
| Active Not Recruiting | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma NCT04587687 | Joseph Tuscano | Phase 2 |
| Completed | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymph NCT04578600 | Joseph Tuscano | Phase 1 |
| Active Not Recruiting | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That H NCT04447716 | Thomas Jefferson University | Phase 1 |
| Recruiting | A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination NCT04224493 | Epizyme, Inc. | Phase 3 |
| Active Not Recruiting | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P NCT04205409 | University of Washington | Phase 2 |
| Active Not Recruiting | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphom NCT04007029 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Withdrawn | CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transp NCT03579927 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas NCT03598998 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participa NCT03583424 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Terminated | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymph NCT03401853 | University of Washington | Phase 2 |
| Active Not Recruiting | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With R NCT03269669 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patient NCT03019640 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. NCT03150329 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma NCT03147885 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Completed | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma NCT02956382 | Georgetown University | Phase 1 / Phase 2 |
| Active Not Recruiting | Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin NCT02992522 | Beth Christian | Phase 1 |
| Active Not Recruiting | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT03015896 | David Bond, MD | Phase 1 / Phase 2 |
| Completed | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT02950220 | Kami Maddocks | Phase 1 |
| Completed | Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma NCT02568553 | National Cancer Institute (NCI) | Phase 1 |
| Completed | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1 NCT02927964 | Robert Lowsky | Phase 1 / Phase 2 |
| Completed | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant NCT02869633 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic L NCT02332980 | Mayo Clinic | Phase 2 |
| Completed | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma NCT01995669 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma NCT01955499 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas NCT01897012 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma NCT01849263 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or R NCT01381692 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099 | Fred Hutchinson Cancer Center | Phase 2 |